Latest news about Zenith Drugs
Zenith Drugs
46.25
+1.20(+2.66%)
Company Performance:
View Company Insights1D+2.66%
1M+18.74%
6M-11.82%
1Y-32.28%
5Y-56.02%
More news about Zenith Drugs
26May 26
Zenith Drugs wins Rs 3.93 crore Karnataka tender
Zenith Drugs Limited secured a Rs 3.93 Crore tender from Karnataka State Medical Supplies Corporation Limited for supplying Oral Rehydration Salts. The order covers 16,388,432 units and strengthens the company's institutional business presence. The disclosure was made under Regulation 30 of SEBI LODR Regulations, 2015.
06May 26
Zenith Drugs Limited Awarded Tender by Madhya Pradesh Public Health Services Corporation
Zenith Drugs Limited secured a Rs. 45,63,145 order from Madhya Pradesh Public Health Services Corporation for supplying 5,14,447 tubes of Mupirocin Ointment. The contract, awarded on May 05, 2026, is not a related party transaction and is expected to enhance operational performance.
26Dec 25
Zenith Drugs Clarifies News Report on NSQ Medicines, States No Government Communication Received
Zenith Drugs has issued a clarification regarding recent news reports about NSQ medicines, stating that the company has not received any communication from government authorities on this matter. The pharmaceutical company's statement aims to address potential confusion arising from media reports and maintain transparency with stakeholders.
18Dec 25
Zenith Drugs Wins ₹95 Million Odisha Tender
Zenith Drugs Limited has won a significant tender worth ₹95 million from the Odisha State Medical Corporation. This contract positions Zenith Drugs as a key supplier to Odisha's state medical infrastructure and demonstrates the company's competitiveness in government procurement processes. The tender win strengthens Zenith Drugs' presence in the government healthcare segment, particularly in eastern India, and adds to its portfolio of institutional clients.
17Mar 25
Zenith Drugs Secures Two Tenders Worth ₹83.3 Crore, Boosting Order Book
Zenith Drugs, a pharmaceutical company, has won two significant tenders totaling ₹83.3 crore. The first tender is valued at ₹68.3 crore, while the second is worth ₹15 crore. This combined value represents 88.3% of the company's current market capitalization of ₹94.3 crore. The substantial order inflow could potentially impact the company's future revenue and profitability, improving its market visibility and industry position.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Dr Reddys Laboratories
Zydus Life Science
Lupin
Mankind Pharma
Aurobindo Pharma
Laurus Labs
1,862.80
(-0.62%)
6,713.50
(-0.59%)
4,516.20
(+0.26%)
1,440.10
(+0.15%)
1,350.50
(+1.66%)
1,101.40
(+0.19%)
2,343.50
(-1.02%)
2,462.30
(-0.83%)
1,555.20
(+1.61%)
1,450.00
(-0.29%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
